Abstract LB-017: HSP110 sustains aberrant NFkB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization

Abstract : Diffuse large B cell lymphoma (DLBCL) is an aggressive lymphoproliferative disorder of B lymphocytes accounting for 30 % of adult Non Hodgkin Lymphoma (NHL). Among DLBCL, Activated B Cell - DLBCL (ABC-DLBCL) is the most aggressive form and has a poor prognosis. Heat-shock proteins (HSPs) are molecular chaperons highly expressed in cancer cells and implicated in resistance to radio- and chemotherapy. Therefore, HSPs are envisioned as therapeutic targets in many cancers. Among the different HSPs, HSP110 has been recently identified as a pro-survival factor in germinal center-derived DLBCL (GC-DLBCL), through stabilization of the GC-DLBCL oncogene Bcl-6. Here, we have explored if HSP110 could also be involved in the survival of the most aggressive form of DLBCL. We observed a high HSP110 expression in all ABC-DLBCL patient samples, compared to normal reactive lymph nodes by using IHC staining of ABC-DLBCL tumor sections and transcriptional analysis of ABC-DLBCL patient tumors. Furthermore, shRNA silencing of HSP110 decreases the survival of several ABC-DLBCL cell lines, and downregulates the expression of pro-survival factors such as BcL2 and BcL-XL. SiRNA silencing of HSP110 abrogates NF-kB signaling, which is the major oncogenic pathway in ABC-DLBCL cell lines. In accord with these results, over-expression of HSP110 in DLBCL and non-DLBCL cell lines increases NF-kB signaling, indicating a tight interplay between HSP110 and the NF-kB pathway. Using immune-precipitation and DuolinkTM assays, we identified an in vitro and in cellulo interaction between HSP110 and Myd88, a critical protein of the NF-kB pathway that bears an activated mutation in many ABC-DLBC patients and that is responsible for lymphoma aggressiveness. Finally, we demonstrate that HSP110 stabilizes the wild type as well as the mutated form of Myd88, therefore facilitating the chronic NF-kB pathway activation in those cells. In conclusion, we identified HSP110 as a regulator of NF-kB signaling through MyD88 stabilization in ABC-DLBCL. This finding highlights HSP110 as a new potential therapeutic target in DLBCL.
Type de document :
Communication dans un congrès
AACR Annual Meeting 2017, Apr 2017, Washington, DC, United States. Cancer Research 77 (13 Supplement), pp.LB-017 - LB-017, 2017, Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. 〈http://cancerres.aacrjournals.org/content/77/13_Supplement/LB-017.article-info〉. 〈10.1158/1538-7445.AM2017-LB-017〉
Liste complète des métadonnées

https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01665396
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : vendredi 15 décembre 2017 - 18:28:33
Dernière modification le : lundi 17 septembre 2018 - 17:30:05

Identifiants

Collections

Citation

Christophe Boudesco, Sebastien Causse, Arlette Hammann, Els Verhoeyen, Laurent Martin, et al.. Abstract LB-017: HSP110 sustains aberrant NFkB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization. AACR Annual Meeting 2017, Apr 2017, Washington, DC, United States. Cancer Research 77 (13 Supplement), pp.LB-017 - LB-017, 2017, Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. 〈http://cancerres.aacrjournals.org/content/77/13_Supplement/LB-017.article-info〉. 〈10.1158/1538-7445.AM2017-LB-017〉. 〈hal-01665396〉

Partager

Métriques

Consultations de la notice

29